{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:46:35Z","timestamp":1792597595516,"version":"4.5.0"},"reference-count":19,"publisher":"Becaris Publishing Limited","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"abstract":"<jats:p>\n                    <jats:bold>Aim:<\/jats:bold>\n                    To compare the hospital-based costs among patients with femoropopliteal artery (FPA) disease treated with Eluvia\u2122 versus Zilver\n                    <jats:sup>\u00ae<\/jats:sup>\n                    PTX\n                    <jats:sup>\u00ae<\/jats:sup>\n                    drug-eluting stents using a large real-world USA hospital database.\n                    <jats:bold>Materials &amp; methods:<\/jats:bold>\n                    This retrospective study included adults in the Premier Healthcare Database who underwent lower extremity FPA endovascular revascularization with Eluvia or Zilver PTX between 1 April 2019 and 31 March 2022. Total hospital-based costs during the index procedure and cumulative 1- and 2-year post-discharge follow-up were compared using multivariable generalized linear models adjusted for age, sex, race and baseline chronic limb-threatening ischemia (CLTI) status. Prespecified subgroup analyses were conducted by care setting (hospital inpatient and hospital outpatient) and among patients with chronic kidney disease (CKD) and CLTI.\n                    <jats:bold>Results:<\/jats:bold>\n                    A total of 7208 patients were included, comprising 4218 treated with Eluvia and 2990 treated with Zilver PTX. Patients treated with Eluvia had a higher prevalence of several comorbidities, including congestive heart failure and CKD. Unadjusted mean hospital-based index procedure costs were similar between groups (Eluvia, $28,631 vs Zilver PTX, $28,359; difference, -$272; p\u00a0=\u00a00.7233). After adjustment, mean index procedure hospital-based costs did not differ significantly between treatment groups ($30,031, p\u00a0=\u00a00.8491). However, Eluvia was associated with lower adjusted cumulative hospital-based costs at the 1-year (difference, $4,017; p\u00a0=\u00a00.0066) and 2-year (difference, $6250; p\u00a0=\u00a00.0021) follow-up. Similar associations were observed in the hospital inpatient and CKD subgroups, whereas no statistically significant differences were observed in the CLTI subgroup.\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    Across patients undergoing femoropopliteal endovascular revascularization, Eluvia was associated with significantly lower post-discharge cumulative hospital-based follow-up costs than Zilver PTX while index procedure costs were comparable. These findings reflect hospital-based costs captured within participating hospitals and do not include medication costs or costs of care received outside the Premier Healthcare Database; therefore, they should not be interpreted as total healthcare costs.\n                  <\/jats:p>","DOI":"10.57264\/cer-2026-0126","type":"journal-article","created":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:59:50Z","timestamp":1792594790000},"source":"Crossref","is-referenced-by-count":0,"title":["Comparative cost analysis of Eluvia\u2122 versus Zilver\n                    <sup>\u00ae<\/sup>\n                    PTX\n                    <sup>\u00ae<\/sup>\n                    in treating femoropopliteal peripheral artery disease utilizing real-world data"],"prefix":"10.57264","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9931-9999","authenticated-orcid":false,"given":"Elizabeth A","family":"Genovese","sequence":"first","affiliation":[{"name":"Division of Vascular Surgery &amp; Endovascular Therapy, University of Pennsylvania, Philadelphia, PA 19104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1982-8417","authenticated-orcid":false,"given":"Abimbola O","family":"Williams","sequence":"additional","affiliation":[{"name":"Boston Scientific, Marlborough, MA 01752, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7040-317X","authenticated-orcid":false,"given":"Ryoko","family":"Sato","sequence":"additional","affiliation":[{"name":"Boston Scientific, Marlborough, MA 01752, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6486-1788","authenticated-orcid":false,"given":"Alysha M","family":"McGovern","sequence":"additional","affiliation":[{"name":"Boston Scientific, Marlborough, MA 01752, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3772-5887","authenticated-orcid":false,"given":"Michael R","family":"Jaff","sequence":"additional","affiliation":[{"name":"Boston Scientific, Maple Grove, MN 55311, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","published-online":{"date-parts":[[2026,10,21]]},"reference":[{"issue":"6","key":"e_1_3_10_3_2","first-page":"362","article-title":"Lower extremity peripheral artery disease: diagnosis and treatment","volume":"99","author":"Firnhaber JM","year":"2019","unstructured":"Firnhaber JM, Powell CS. Lower extremity peripheral artery disease: diagnosis and treatment. Am. Fam. Physician 99(6), 362\u2013369 (2019).","journal-title":"Am. Fam. Physician"},{"key":"e_1_3_10_4_2","doi-asserted-by":"crossref","first-page":"8295054","DOI":"10.1155\/2019\/8295054","article-title":"Burden of coronary artery disease and peripheral artery disease: a literature review","volume":"2019","author":"Bauersachs R","year":"2019","unstructured":"Bauersachs R, Zeymer U, Briere JB, Marre C, Bowrin K, Huelsebeck M. Burden of coronary artery disease and peripheral artery disease: a literature review. Cardiovasc. Ther. 2019, 8295054 (2019).","journal-title":"Cardiovasc. Ther."},{"key":"e_1_3_10_5_2","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2147\/VHRM.S209241","article-title":"The burden of critical limb ischemia: a review of recent literature","volume":"15","author":"Duff S","year":"2019","unstructured":"Duff S, Mafilios MS, Bhounsule P, Hasegawa JT. The burden of critical limb ischemia: a review of recent literature. Vasc. Health Risk Manag. 15, 187\u2013208 (2019).","journal-title":"Vasc. Health Risk Manag."},{"issue":"3","key":"e_1_3_10_6_2","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1253\/circj.CJ-16-1286","article-title":"Pathophysiology of intermittent claudication in peripheral artery disease","volume":"81","author":"Hamburg NM","year":"2017","unstructured":"Hamburg NM, Creager MA. Pathophysiology of intermittent claudication in peripheral artery disease. Circ. J. 81(3), 281\u2013289 (2017).","journal-title":"Circ. J."},{"key":"e_1_3_10_7_2","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.atherosclerosis.2019.05.026","article-title":"Cost and inpatient burden of peripheral artery disease: Findings from the National Inpatient Sample","volume":"286","author":"Kohn CG","year":"2019","unstructured":"Kohn CG, Alberts MJ, Peacock WF, Bunz TJ, Coleman CI. Cost and inpatient burden of peripheral artery disease: Findings from the National Inpatient Sample. Atherosclerosis 286, 142\u2013146 (2019).","journal-title":"Atherosclerosis"},{"issue":"11","key":"e_1_3_10_8_2","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.clinthera.2023.09.021","article-title":"Peripheral artery disease: underappreciated impact and residual cardiovascular risk despite revascularization","volume":"45","author":"Jansen S","year":"2023","unstructured":"Jansen S, de Borst GJ, Hinchliffe R, Teraa M. Peripheral artery disease: underappreciated impact and residual cardiovascular risk despite revascularization. Clin. Ther. 45(11), 1019\u20131022 (2023).","journal-title":"Clin. Ther."},{"issue":"4","key":"e_1_3_10_9_2","first-page":"100341","article-title":"Intravascular lithotripsy for peripheral artery calcification: mid-term outcomes from the randomized Disrupt PAD III trial","volume":"1","author":"Tepe G","year":"2022","unstructured":"Tepe G, Brodmann M, Bachinsky W Intravascular lithotripsy for peripheral artery calcification: mid-term outcomes from the randomized Disrupt PAD III trial. J. Soc. Cardiovasc. Angiogr. Interv. 1(4), 100341 (2022).","journal-title":"J. Soc. Cardiovasc. Angiogr. Interv."},{"issue":"10","key":"e_1_3_10_10_2","doi-asserted-by":"crossref","first-page":"108910","DOI":"10.1016\/j.jvir.2026.108910","article-title":"Comparison of three-year US payer costs for endovascular treatment options to treat femoropopliteal artery disease","volume":"37","author":"Lyden SP","year":"2026","unstructured":"Lyden SP, Vanden Baviere H, Martinson M, Wheatley M, Tarra T, Gray WA. Comparison of three-year US payer costs for endovascular treatment options to treat femoropopliteal artery disease. J. Vasc. Interv. Radiol. 37(10), 108910 (2026).","journal-title":"J. Vasc. Interv. Radiol."},{"issue":"9","key":"e_1_3_10_11_2","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1007\/s00270-021-02848-8","article-title":"A budget impact model for the use of drug-eluting stents in patients with symptomatic lower-limb peripheral arterial disease: an Australian perspective","volume":"44","author":"Altaf N","year":"2021","unstructured":"Altaf N, Ariyaratne TV, Peacock A A budget impact model for the use of drug-eluting stents in patients with symptomatic lower-limb peripheral arterial disease: an Australian perspective. Cardiovasc. Intervent. Radiol. 44(9), 1375\u20131383 (2021).","journal-title":"Cardiovasc. Intervent. Radiol."},{"issue":"3","key":"e_1_3_10_12_2","doi-asserted-by":"crossref","first-page":"znaf274","DOI":"10.1093\/bjs\/znaf274","article-title":"Plain balloon angioplasty with or without bare-metal stenting versus drug-coated balloon angioplasty with or without bare-metal stenting versus primary drug-eluting stenting in patients requiring femoropopliteal, with or without infrapopliteal, endovascular revascularization for chronic limb-threatening ischaemia: BASIL-3 within-trial health economic analysis","volume":"113","author":"Javed M","year":"2026","unstructured":"Javed M, Kigozi J, Moakes CA Plain balloon angioplasty with or without bare-metal stenting versus drug-coated balloon angioplasty with or without bare-metal stenting versus primary drug-eluting stenting in patients requiring femoropopliteal, with or without infrapopliteal, endovascular revascularization for chronic limb-threatening ischaemia: BASIL-3 within-trial health economic analysis. Br. J. Surg. 113(3), znaf274 (2026).","journal-title":"Br. J. Surg."},{"issue":"10157","key":"e_1_3_10_13_2","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(18)32262-1","article-title":"A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial","volume":"392","author":"Gray WA","year":"2018","unstructured":"Gray WA, Keirse K, Soga Y A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial. Lancet 392(10157), 1541\u20131551 (2018).","journal-title":"Lancet"},{"issue":"3","key":"e_1_3_10_14_2","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/s00270-020-02693-1","article-title":"Two-year efficacy and safety results from the IMPERIAL randomized study of the Eluvia polymer-coated drug-eluting stent and the Zilver PTX polymer-free drug-coated stent","volume":"44","author":"M\u00fcller-H\u00fclsbeck S","year":"2021","unstructured":"M\u00fcller-H\u00fclsbeck S, Benko A, Soga Y Two-year efficacy and safety results from the IMPERIAL randomized study of the Eluvia polymer-coated drug-eluting stent and the Zilver PTX polymer-free drug-coated stent. Cardiovasc. Intervent. Radiol. 44(3), 368\u2013375 (2021).","journal-title":"Cardiovasc. Intervent. Radiol."},{"issue":"1","key":"e_1_3_10_15_2","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1080\/13696998.2022.2088965","article-title":"Cost-effectiveness of a paclitaxel-eluting stent (Eluvia) compared to Zilver PTX for endovascular femoropopliteal intervention","volume":"25","author":"Gray WA","year":"2022","unstructured":"Gray WA, Griffiths RI, Elroy PWM Cost-effectiveness of a paclitaxel-eluting stent (Eluvia) compared to Zilver PTX for endovascular femoropopliteal intervention. J. Med. Econ. 25(1), 880\u2013887 (2022).","journal-title":"J. Med. Econ."},{"key":"e_1_3_10_16_2","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2024-0025"},{"key":"e_1_3_10_17_2","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.avsg.2018.05.051","article-title":"Comparison of the cost of drug-eluting stents versus bare metal stents in the treatment of critical limb ischemia in the United States","volume":"55","author":"Locham SS","year":"2019","unstructured":"Locham SS, Paracha N, Dakour-Aridi H, Nejim B, Rizwan M, Malas MB. Comparison of the cost of drug-eluting stents versus bare metal stents in the treatment of critical limb ischemia in the United States. Ann. Vasc. Surg. 55, 55\u201362 (2019).","journal-title":"Ann. Vasc. Surg."},{"issue":"5","key":"e_1_3_10_18_2","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/j.jvs.2018.02.040","article-title":"Implementation of drug-eluting stents for the treatment of femoropopliteal disease provides significant cost-to-system savings in a single-state outpatient simulation","volume":"68","author":"Sridharan ND","year":"2018","unstructured":"Sridharan ND, Liang N, Robinson D Implementation of drug-eluting stents for the treatment of femoropopliteal disease provides significant cost-to-system savings in a single-state outpatient simulation. J. Vasc. Surg. 68(5), 1465\u20131472 (2018).","journal-title":"J. Vasc. Surg."},{"issue":"5","key":"e_1_3_10_19_2","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson ME","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic Dis. 40(5), 373\u2013383 (1987).","journal-title":"J. Chronic Dis."},{"issue":"1","key":"e_1_3_10_20_2","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000521288","article-title":"Charlson comorbidity index: a critical review of clinimetric properties","volume":"91","author":"Charlson ME","year":"2022","unstructured":"Charlson ME, Carrozzino D, Guidi J, Patierno C. Charlson comorbidity index: a critical review of clinimetric properties. Psychother Psychosom. 91(1), 8\u201335 (2022).","journal-title":"Psychother Psychosom."},{"key":"e_1_3_10_21_2","unstructured":"US Bureau of Labor Statistics. Consumer price index for all urban consumers (CPI-U). (2024). https:\/\/data.bls.gov\/timeseries\/CUUR0000SAM"}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2026-0126","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:59:53Z","timestamp":1792594793000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2026-0126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,21]]},"references-count":19,"alternative-id":["10.57264\/cer-2026-0126"],"URL":"https:\/\/doi.org\/10.57264\/cer-2026-0126","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,21]]},"article-number":"e260126"}}